Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202493 | 0.90 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL20202497 | 0.87 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL18199762 | 0.84 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL18199573 | 0.83 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL20202494 | 0.82 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL18199759 | 0.82 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL1996647 | 0.82 | CHRM3 (0.69) | CHRM3 | |
| SCHEMBL1996643 | 0.82 | CHRM3 (0.69) | CHRM3 | |
| SCHEMBL18199578 | 0.81 | CHRM3 (1.00) | CHRM3 | |
| SCHEMBL18199760 | 0.80 | CHRM3 (1.00) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2016173817-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | UNILEVER PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | MKI67, CUTA, PLP2 | CHRM3 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.